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Background
Acute graft-versus-host disease is a severe complication of allogeneic stem cell transplantation
in which the functional immune cells of the donor recognize the recipient as foreign and mount
an immunological attack. There is an urgent need for better diagnostic instruments for the
assessment of acute graft-versus-host disease. In the present study, a novel bioinformatics
framework was used to identify gene expression patterns associated with acute graft-versus-
host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
Design and Methods
Peripheral blood cells were collected prospectively from patients who did develop acute graft-
versus-host disease (YES) and from those who did not (NO). Gene expression profiling was per-
formed using a panel of 47 candidate genes potentially involved in alloreactive responses. The
entire population of YES/NO acute graft-versus-host disease patients formed the experimental
validation set. Personalized modeling based on a gene selection technique was applied to iden-
tify the most significant mRNA transcripts, which were then used to profile individual data
samples for training and testing the classification/prediction framework.
Results
A leave-one-out cross-validation procedure was performed to investigate the robustness of the
classification framework producing the following results: 100% on the training dataset and
97% on the testing dataset. According to our integrated methodology, transcripts for FOXP3,
ICOS, CD52 and CASP1, genes involved in immune alloreactive responses and participating in
immune cell interactions, were identified as the most informative biomarkers in allogeneic
stem cell transplant recipients experiencing acute graft-versus-host disease.
Conclusions
This study demonstrates that the integrated methodology proposed is useful for the selection
of valid gene targets for the diagnosis of acute graft-versus-host disease, producing satisfactory
accuracy over independent clinical features of the allogeneic transplanted population. 
Key words: stem cell transplantation, graft-versus-host-disease, computational method, gene
expression profile.
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ABSTRACT
Introduction
The establishment of the donor's immune system in an
antigenically distinct recipient undergoing allogeneic
hematopoietic stem cell transplantation (HSCT) confers
a desired therapeutic graft-versus-tumor effect. It can,
however, also result in detrimental acute graft-versus-
host disease (aGvHD) associated with a high rate of
transplant-related mortality. The aGvHD phenomenon
occurs classically within 100 days after transplantation
and is mainly associated with the clinical consequences
of an immune-mediated attack or “cytokine storm” of
target tissues including the gastrointestinal tract, liver
and skin. 
More specifically, aGvHD is a complex disease result-
ing from donor T-cell recognition of a genetically dis-
parate recipient that is unable to reject donor cells follow-
ing allogeneic HSCT.1 In fact, the induction of aGvHD is
dependent on the presentation of host alloantigens by
antigen-presenting cells to naïve donor T cells.2
Unfortunately, the clinical diagnosis of aGvHD is not
always straightforward or easy to establish, and skin or
intestinal biopsies are required to confirm the diagnosis.
Consequently, therapeutic strategies based on the sup-
pression of critical molecular pathways involved in T-cell
activation and the clinical manifestation of aGvHD may
lead to unnecessary over-treatment by clinicians.
Extensive research is currently underway to identify
blood-based biomarkers of aGvHD using novel tools
including proteomic and molecular methods.3,4 In this
respect, proteomic analysis has identified several serum
proteins as potential biomarkers of multi-organ aGvHD.
One promising biomarker, Elafin protein, has been pro-
posed to have significant diagnostic and prognostic value
specifically for skin GvHD.5 Recently, a strong association
was observed between soluble tumor necrosis factor
receptor 1 (sTNFR1) levels and the development of
aGvHD, although the low sensitivity of sTNFR1 determi-
nation reduces the clinical utility of this biomarker.6
Donor gene-expression profiles (GEP) can also be used to
predict the occurrence of chronic GvHD in the recipient.7
Although only a pilot study, Buzzeo et al. identified a GEP
signature of aGvHD, independent of tissue localization,
in patients undergoing allogeneic HSCT.8
In the present study, we evaluated the gene expression
levels of a complex panel of 47 functional candidate genes
hypothesized to be involved in immune alloreactive
responses in aGvHD.9 We examined the applicability of
GEP analysis for supporting the diagnosis of aGvHD at
presentation of symptoms with multiple targets and
severity. 
Although transcriptional profiles may be obtained from
many human tissues, the status of the immune system
can be best monitored by profiling transcripts in the
blood. We, therefore, chose to use unselected peripheral
blood cell (PBC) samples, which have the advantage of
being easily accessible and offering a non-invasive way of
monitoring molecular changes safely.
The major objective of our study was to determine
whether GEP could be used to discriminate, at the onset
of a clinical suspicion of aGvHD, those allogeneic HSCT
recipients who will develop aGvHD from those who will
not. A novel computational framework previously pre-
sented in the technical literature10,11 was applied in this
study.
Design and Methods
Patients and graft characteristics  
In this single center study we included 59 consecutive patients
who received allogeneic transplants between 2007 and 2010.
Hematopoietic progenitor cells were collected by apheresis and
used as stem cells in 44 cases, whereas in 15 transplants the
source of stem cells was bone marrow. The characteristics of the
patients, transplants and grafts are presented in Table 1.
Any GvHD before day100 was classified as acute. The sever-
ity was categorized as grade I-IV according to modified
Glucksberg criteria (A-D by the International Bone Marrow
Transplant Registry index).12,13 The diagnosis of aGvHD was
confirmed by skin or gastrointestinal biopsy in all cases.
Prophylaxis for aGvHD consisted mainly of cyclosporine A (2
mg/kg on day -1, 1 mg/kg from day 0) combined with a short-
term course of methotrexate: 15 mg/m2 on day +1, and 10 mg/m2
on days +3 and +6 and also on day +11 in the case of mild-mod-
erate mucositis. In the case of an alternative donor, anti-lympho-
cytic serum at a total variable dose ranging from 4.5-15 mg/kg
was added to the conditioning regimens for in vivo T-cell deple-
tion. In the case of total lymph-node irradiation plus antithymo-
cyte globulin, methotrexate was replaced by mycophenolate
mofetil at a maximum dose of 2 g daily. For patients undergoing
haploidentical transplantation, aGvHD prophylaxis consisted of
cyclophosphamide 50 mg/kg on days +3 and +4 followed by
tacrolimus and mycophenolate mofetil.
Experimental design and sampling
The study was approved by the local Ethics Committee and
the procedures followed were in accordance with the World
Medical Association’s Helsinki Declaration. PBC were collected
from all patients +15, +30, +45, +60, +90 and +120 days after
HSCT and at each event compatible with suspected aGvHD.
Overall, 400 samples were collected. Because the experimental
design plays a crucial role in the search for useful biomarkers,
the first step was to choose the most informative specimens. To
this end, we selected those samples obtained upon observation
of the first clinical symptoms and which were confirmed by
biopsy. Positive cases of aGvHD (YES) and controls negative for
aGvHD (NO) were matched to avoid bias due to immunosup-
pressive treatment. This matching was best achieved using a
database containing high-quality samples linked to quality con-
trolled clinical information. We used 23 samples from aGvHD
(YES) patients obtained at diagnosis and before any anti-aGvHD
therapy and we selected 36 samples from patients who did not
experience aGvHD (NO). Recipients were regarded as not hav-
ing developed aGvHD when they remained at least 120 days
without presenting any aGvHD events. The entire group of
YES/NO patients formed the validation population for subse-
quent modeling studies.
Biological samples RNA extraction, low density 
gene expression assay
Total RNA was extracted from PBC samples using the
RNAeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. Purified RNA was reverse transcribed using the
High Capacity cDNA Archive kit with random primers (Applied
Biosystems), and a multigene expression assay was carried out
with a TaqMan® Low Density Array Fluidic card (TLDA-card) on
the PRISM Real-Time 7900HT Sequence Detection system plat-
form (Applied Biosystems), according to the manufacturer’s
instructions. For the TLDA-card, we selected 47 candidate
genes9 (Online Supplementary Table S1) involved in the immune
network and in the pathogenesis of inflammation; 18S was con-
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sidered the endogenous reference gene. A pool of PBC from ten
healthy volunteers was used to obtain cDNA to be used as the
calibrator for the assay. Expression of each gene transcript was
measured in triplicate and then normalized to the calibrator
sample. 
Quantitative real-time polymerase chain reaction, 
single assay
Total RNA was extracted from PBC samples or healthy donors
and cDNA was obtained as described above. The levels of expres-
sion of FOX-P3 (ID 00203958_A1) and ICOS (ID 00359999_A1)
were determined using primers and probes from Applied
Biosystems (ABI Assays on Demand; http://www.appliedbiosys-
tems.com/). The 18S pre-developed TaqMan assay (99999901_S1)
was used as the endogenous control. All gene expression assays
were performed on the ABI PRISM Real-Time 7900HT Sequence
Detection system (Applied Biosystems). The relative expression
level of target genes was determined using the ΔΔCT method.
Immunohistochemical analysis
Immunohistochemical staining was performed on 3 µm thick
serial sections cut from formalin-fixed and paraffin-embedded tis-
sues. Conditions were optimized for each primary antibody: anti-
FOXP3 (mouse monoclonal antibody, Abcam) and anti-ICOS
(rabbit monoclonal antibody, Spring Bioscence). Antigen retrieval
was performed in a temperature-controlled water bath at 98 °C
with EDTA pH 9/citrate buffer pH 6 and antibody binding was
visualized using an EnVision™ Detection System, Peroxidase
(DAKO) with DAB as the chromogen. Tonsil and lymph node
were used as positive controls for FOXP3 and ICOS, respectively.
The negative control was included with each run by substituting
the primary antibody with non-immune rabbit serum. The con-
trol sections were treated in parallel with the samples.
Personalized modeling for identification of target genes
in acute graft-versus-host disease
With the aim of identifying the most informative genes able to
detect aGvHD at the onset of clinical signs, we proceeded to bet-
ter define our dataset by pre-processing experimental variables
such as race, disease, stem cell source, HLA tissue typing, number
of mismatched loci between donor/recipient, donor/recipient age,
donor/recipient sex, conditioning intensity, and donor/recipient
blood group. In this study, we used a novel personalized modeling
based gene selection (PMGS) method,11 previously developed for
GEP data tailored to the diagnosis/classification of aGvHD.
Personalized modeling is a relatively new method in bioinformat-
ics research and published information based on this method is
still fairly sparse. Representative works have been published by
Song and Kasabov.14,15
The main objective of personalized modeling is to create a
model for each patient (sample), which is able to reveal the most
important information specifically for each sample, focusing
attention on the individual patient (sample) rather than simply on
the global problem space.16,17
Previous works have reported that personalized modeling can
produce better classification results than those obtained from clas-
sical global modeling,14,16,18 making it more appropriate to build
clinical decision support systems for new patients. The frame-
work proposed by Fiasché et al.11,19 used a “personalized” wrap-
ping method, a PMGS described in detail in recent papers20,21 for
gene expression data analysis, integrating new data with the exist-
ing models; the block diagram is reported in Figure 1. We used
weighted-weighted distance K-nearest neighbor (WWKNN) as
the classification algorithm15 given that the simple weighted dis-
tance K-nearest neighbor (WKNN) algorithm had returned better
results than other classification techniques in previous experi-
ments (an interesting comparison is reported by Fiasché’s
group).11,19,20
Finally, a compact genetic algorithm22 was used to optimize the
learning function during the training process making framework
performances useful in clinical applications.
Statistical analysis 
Results of quantitative relative real-time polymerase chain reac-
tion, performed as single assays, were used to calculate the area
under the curve (AUC) by receiver operating characteristic (ROC)
analysis for FOXP3 and ICOS expression levels. Statistical analy-
ses were performed using the SPSS software package for
Windows, release v13.0, 2004 (SPSS, UK).
m. Cuzzola et al.
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Table 1. Main hematologic characteristics of the HSCT recipients,
transplant properties, conditioning regimens, prophylaxis and treat-
ments of aGvHD.
Number of patients 59
Sex (male/female) 31/28
Median age (range) 43 (14-70)
Diagnosis
Acute myeloid leukemia/acute lymphoblastic leukemia 29/9
Chronic myeloid leukemia/myelodysplastic syndrome 5/1
Non-Hodgkin’s lymphoma/Hodgkin’s lymphoma 3/2
Chronic lymphocytic leukemia 6
Myelofibrosis/chronic myelomonocytic leukemia 1/1
Paroxysmal nocturnal hemoglobinuria/multiple myeloma 1/1
Disease status at allogeneic HSCT
CR/PR/PD 19/39/1
Donor type
Median age (range) 43 (14-70)
Sex (male/female) 38/21
Sibling HLA-identical 43
Alternative HLA- identical 8
Alternative HLA- mismatched 2
Haploidentical 6
Conditioning regimens
Myeloablative conditioning 27
Reduced intensity conditioning 32
aGvHD YES/NO 23/36
Type: skin/gut 20/3
Grade I/ II/ III 5/14/4
aGvHD prophylaxis 59
Cyclosporine A + methotrexate 36
Cyclosporine A + mycophenolate 19
Tacrolimus + mycophenolate 3
None 1
Graft-versus-host disease treatments
Prednisone 17
Prednisone + extracorporeal photoapheresis 5
Prednisone + infliximab 1
Duration; days (range) 44.7 (16-75)
CR: complete remission; PR: partial remission; PD: progressive disease.
Results
Personalized modeling-based gene selection identified
FOXP3, ICOS, CD52 and CASP1 as the most 
informative gene transcripts associated with 
acute graft-versus-host disease 
In our attempt to determine a gene expression signature
that is diagnostic of aGvHD, we first correlated global GEP
data obtained from the TLDA-card with the occurrence of
aGvHD in allogeneic HSCT recipients at the onset of clin-
ical signs. A heat-map of differentially expressed genes is
shown in Online Supplementary Figure S1. Since simple sta-
tistical analysis or classical data-mining techniques failed to
identify a specific gene pattern, we used computational
intelligence methods according to previously published
algorithms.17,19,20 The PMGS approach was applied to the
data obtained from the TLDA-card to identify a group of
genes to represent the data set. In our framework the most
important genes selected for each patient may differ (per-
sonalized subset), but during our analysis, it was evident
that for each run, four genes were always present in the
entire subset of patients who did develop aGvHD. The fol-
lowing genes were always identified with other clinical
variables: FOXP3 (a member of the forkhead transcription-
al factor family), ICOS (a CD28 homolog termed inducible
co-stimulator), CD52 and CASP1 (caspase 1 or apoptosis-
related cysteine peptidase). Notably, the leave-one-out
cross-validation (LOOCV) testing procedure system had an
accuracy of 97%, specificity of 0.96, and sensitivity of 1.
Application of the personalized modeling-based gene
selection method identified the characteristics of
patients with acute graft-versus-host disease
The new model, created for each step, was trained
(D0tr) with the personalized model for 59 runs and a
LOOCV (97% for the integrated method) was calculated
for the new dataset D, obtained by adding a new sample
for each new run. A scenario of personalized feature
weights is shown in Table 2. It is evident that HLA tissue
typing, number of mismatched loci and age are relevant
characteristics in the personalized approach making it pos-
sible to select a very low number of transcript genes with
good classification results. Another important observation
was made from our experimental computational analysis,
as shown in the scenario in Table 2 for two samples repre-
sentative of the whole dataset, which, however, differed
in our personalized modeling for the sex variable. In our
personalized analysis, age had a different weight in male
and female subjects. Indeed, in female subjects, “age at
transplantation” correlated with the features “donor age”
and “blood group”, which were more important (higher
weight) in female subjects than in male ones. Finally, we
must highlight that the gene transcript subgroups:
(FOXP3, CASP1) and (ICOS, CASP1), selected with the
clinical variables above, returned a classification result
with an accuracy of 86%. 
An example demonstrating how PMGS can present the
analysis results from a data sample is provided in Figure 2.
For four sample-patients, the PMGS method selected three
genes as the best subgroup (CASP1, FOXP3, ICOS) and
(FOXP3, ICOS, CD52) and the classifier successfully pre-
dicted corresponding samples as diseased.19 It is easy to
appreciate that a sample is more likely to be in the dis-
eased group, since most of its nearest neighbors belong to
the diseased group.
Gene expression assay confirmed low expression of
FOXP3 and ICOS in acute graft-versus-host disease 
All patients’ samples identified as aGvHD (YES) or (NO)
included in the validation setting were simultaneously
quantified by gene expression assays for FOXP3 and ICOS
FOXP3, ICOS, CD52 and CASP1 in aGvHD
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Figure 1. A block diagram repre-
senting the PMGS algorithm.
Table 2. A scenario of “personalized” models for two different sub-
groups, female (F) and male (M), comparing with weight of variables
and genes obtained with global modeling. 
Subject 1 (F) Subject 2 (M) Global
Input variables weights of weights of weights/
input variables input variables importance
(F + M)
Age (years) 0.9101 0.7025 0.7127
HLA type (g/L) 0.8521 0.8447 0.8429
Number of mismatched loci 0.9507 0.8452 0.8769
Conditioning regimen 0.7478 0.752 0.8104
FOXP3 0.9617 0.9269 0.9254
ICOS 0.7295 0.8641 0.8228
CASP1 0.8651 0.7459 0.8096
CD52 0.8797 0.8802 0.9009
Actual output
Predicted output with PMGS 0.95 1.01
Data Dx Personalized gene
selection method (e.g.
WKNN, WWKNN)
Personalized gene
subset g0
Evalutating prediction
accuracy
Output selected gene
subsetA learning machine
model (e.g. cGA
optimizer)
Neighbourhood
Dpers
X
Unsatisfied
Satisfied
transcripts. ROC curve analysis was used to identify the
best informative transcripts associated with aGvHD
resulting from the computational algorithm (Figure 3).
Since we demonstrated that the levels of expression of
FOXP3 and ICOS were very different between aGvHD
YES and NO subsets, we also determined the minimum
expression level that indicated the aGvHD NO condition.
Specifically, the cut-off value of the relative expression
level of target gene was 1.40 for FOXP3 (AUC=0.745,
P=0.002) and 1.44 for ICOS (AUC=0.944, P<0.0001).
Immunohistochemical analysis confirmed the presence
of low levels of FOXP3 and ICOS proteins in cutaneous
biopsies from patients with acute graft-versus-host
disease.
In a subset of ten patients with histologically confirmed
aGvHD we evaluated FOXP3 and ICOS protein expres-
sion by immunohistochemistry in formalin-fixed, paraf-
fin-embedded skin tissue biopsies. In all cases, rare
FOXP3+ lymphocytes and scattered ICOS+ activated lym-
phocytes were observed at the dermo-epidermal junction,
in the superficial dermis and around the adnexal follicular
epithelium (Figure 4).
Discussion
In our study we used dynamic genomic markers derived
from peripheral blood gene expression profiling to devel-
op an instrument for assessing aGvHD quickly and non-
invasively. Not only is blood easier to obtain than tissue,
but it also contains a number of circulating cell types that
are mechanistically associated with immunological dis-
ease processes.23
It is interesting that in addition to the more well-known
mechanisms involved in aGvHD,24 novel players have
recently been discovered, such as CASP1 and FOXP3,
supported by an intense body of research which has pro-
vided compelling evidence for their correlation with
aGvHD.9,25 For example, a humanized monoclonal anti-
body against CD52 has been widely used for preventing
aGvHD in allogeneic HSCT.26 Notably, CD52 signaling is
correlated with induction of CD4+ regulatory T cells,27
and FOXP3 is the major gene transcript representative of
CD4+/CD25+/CD127- Treg. In our study, FOXP3 and ICOS
were the most informative genes selected by PMGS. These
findings were then validated by single gene expression
assays, which showed significant AUC values for FOXP3
and ICOS and cut-off values suggestive of the occurrence
of aGvHD. Notably, immunohistochemical analyses, per-
formed on cutaneous biopsy specimens from aGvHD
(YES) patients, showed small amounts of FOXP3 and
ICOS proteins, in accordance with the observed low
expression of their molecular transcripts.
In clinical practice the low expression levels of these
genes could be helpful for discriminating patients who are
developing aGvHD from those who are not. In addition,
we observed that, in patients with aGvHD who under-
went anti-aGvHD treatments, the number of copies of
FOXP3 and ICOS increased in patients responding to
treatment (data not shown). This phenomenon also
occurred for genes regulated by ICOS, including T-helper
(Th)2 cytokines (i.e.IL-4, STAT-6, IL-18). This finding is
supported by the fact that Th2 cell therapy can rapidly
improve severe aGvHD via IL-4- and IL-10-mediated
mechanisms.28 Thus, determining the levels of FOXP3 and
ICOS gene expression may represent a molecular
m. Cuzzola et al.
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Figure 2. Visualization of the results of
the decision making framework with
three genes: triangular point, actual
value of this sample; upward square
points, healthy; downward circle
points, diseased. Examples of incre-
mental-personalized-method during
the execution of the run: (A) sample
with ID 8, (B) sample with ID 20, (C)
sample with ID 3, (D) sample with ID
14. Note: the values on x and y axes
are normalized to 0 and  1.
BA
C D
approach to monitoring the efficacy of therapy in allo-
geneic HSCT recipients with aGVHD. This could be of
clinical value, since the method used in this study may
identify patients with a deteriorating acute syndrome,
despite the administration of corticosteroids. We found
that the ICOS gene was down-regulated during aGvHD in
allogeneic HSCT recipients, which is a novel observation
in humans. Previously, Buzzeo et al.8 observed that the
human ICOS ligand was down-regulated during the onset
of aGvHD, but changes in ICOS expression have never
been reported.
Great attention is placed on the role of ICOS in the
pathophysiology of aGvHD. ICOS is a CD28/cytotoxic T
lymphocyte antigen 4 (CTLA-4) family member expressed
on activated T cells.29 The role of ICOS in aGvHD is con-
troversial. In experimental mice models, ICOS exacerbat-
ed Th1-mediated aGvHD30 while another animal study
demonstrated that ICOS blockade had positive effects on
inhibiting aGvHD. In contrast, Witsch showed that the
ICOS signal inhibits the development of aGvHD mediated
by CD8+ effector cells in myeloablative bone marrow
transplantation.31,32
From a clinical standpoint, the best transcript gene tar-
gets prioritized by computational systems for the assess-
ment of immunological alloreactions in HSCT patients are
also very robust since they exhibit the same behavior even
in the presence of confounding factors related to sex or
HLA donor-disparity, transplant conditioning and co-mor-
bidity such as viral infection. In fact, the expression levels
of the most informative genes were not influenced in the
subset of patients who were positive for DNA
cytomegalovirus (data not shown). We observed that this
model was applicable to all cases of aGvHD including four
cases of grade III aGvHD. Moreover, the level of expres-
sion of the four most informative genes showed a slight
trend in correlating with non-relapse related mortality
(data not shown).
The transferability of the aGvHD-linked gene-expres-
sion profiles might suggest a major epigenetic influence
rather than an environmental one. However, higher-order
predictive variable combinations do require the support of
many more samples in order to prevent over-fitting of the
model. Convincing assessment of this issue will, therefore,
require expression profiling of the genes identified here in
larger cohorts of participants and validation by other cen-
ters before it can be widely used to guide clinical decision-
making processes.
In conclusion, our results could lay the basis for a novel
approach in transplantation medicine by contributing to
the differentiation of an immune reaction from other mor-
bidities and to tailoring immunosuppressive regimens.
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